Classifications to enable rapid peer-group analysis of companies.
Evaluate builds up product sales estimates from leading brokers, to create a consensus sales forecast.
Comprehensive deals dataset for biopharma alliances including all top-level financial information.
Evaluate proprietary technologies and vocabularies have been used to generate granular disease classifications for products and documents.
Dynamic Consensus Forecast provides near-time updates to consensus drug forecasts, annual estimates with a 10-year forecast horizon and quarterly projections.
Evaluate has reviewed all companies and applied a robust rule-based methodology to define lead asset.
Market Access provides information for US-launched products with benchmarks by EphMRA code, technology and mechanism of action.
Medical literature data from the pharmaceutical industry to provide a greater depth of insight into product and disease developments.
All products with orphan designations based on analysis of FDA (USA), EMA (Europe) and NIBIO (Japan) orphan designation data sets, integrated and standardized.
Consolidated US pack pricing, current cost-per-patient values and benchmarks by indication, technology and mechanism of action.
A directional estimate of the cost of running Phase I, II and III clinical trials at both a trial and a product level.
Analysis on approx. 70% of Evaluate products with sales, to reveal the indication specific dynamic behind historic and forecast sales.
Evaluate’s Technology classifications and definitions.
Estimated phase progression and approval dates for products by indication.
Benchmark launch performances of new assets and model the likely market penetration pattern of a new product as part of the forecasting process.
Insight into the pricing and volume dynamic behind USA drug sales, integrating pricing and volume datasets and via a proprietary methodology to reveal the volume and pricing measures on key drugs.